Target Discovery Using Deep Learning-Based Molecular Docking and Predicted Protein Structures With AlphaFold for Novel Antipsychotics

키워드

참고문헌 (73)

1. Vigo D, "Estimating the true global burden of mental illness", Lancet Psychiatry, 3, pp.171~178 (2016)
2. Charlson FJ, "Global epidemiology and burden of schizophrenia : findings from the global burden of disease study 2016", Schizophr Bull, 44, pp.1195~1203 (2018)
3. Hyman SE, "Psychiatric drug development : diagnosing a crisis", Cerebrum, 2013, pp.5~ (2013)
4. Huhn M, "Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders : a systematic overview of meta-analyses", JAMA Psychiatry, 71, pp.706~715 (2014)
5. Conley RR, "Management of treatment resistance in schizophrenia", Biol Psychiatry, 50, pp.898~911 (2001)
6. Nielsen J, "Optimizing clozapine treatment", Acta Psychiatr Scand, 123, pp.411~422 (2011)
7. Juul Povlsen U, "Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years", Acta Psychiatr Scand, 71, pp.176~185 (1985)
8. Pratt J, "Advancing schizophrenia drug discovery : optimizing rodent models to bridge the translational gap", Nat Rev Drug Discov, 11, pp.560~579 (2012)
9. Roth BL, "Magic shotguns versus magic bullets : selectively non-selective drugs for mood disorders and schizophrenia", Nat Rev Drug Discov, 3, pp.353~359 (2004)
10. Javitt DC, "Neurophysiological biomarkers for drug development in schizophrenia", Nat Rev Drug Discov, 7, pp.68~83 (2008)
11. Jafari S, "Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects", J Neurochem, 120, pp.371~384 (2012)
12. Keepers GA, "The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia", Am J Psychiatry, 177, pp.868~872 (2020)
13. Verdolini N, "Long-term treatment of bipolar disorder type I : a systematic and critical review of clinical guidelines with derived practice algorithms", Bipolar Disord, 23, pp.324~340 (2021)
14. Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
15. Nair PC, "Binding of clozapine to the GABAB receptor : clinical and structural insights", Mol Psychiatry, 25, pp.1910~1919 (2020)
16. Khokhar JY, "Unique effects of clozapine : a pharmacological perspective", Adv Pharmacol, 82, pp.137~162 (2018)
17. Revel FG, "A new perspective for schizophrenia : TAAR1 agonists reveal antipsychotic-and antidepressant-like activity, improve cognition and control body weight", Mol Psychiatry, 18, pp.543~556 (2013)
18. Koblan KS, "A Non-D2-receptor-binding drug for the treatment of schizophrenia", N Engl J Med, 382, pp.1497~1506 (2020)
19. McNutt AT, "GNINA 1. 0 : molecular docking with deep learning", J Cheminform, 13, pp.43~ (2021)
20. Sunseri J, "Virtual screening with Gnina 1. 0", Molecules, 26, pp.7369~ (2021)
21. Jumper J, "Highly accurate protein structure prediction with AlphaFold", Nature, 596, pp.583~589 (2021)
22. Agid Y, "How can drug discovery for psychiatric disorders be improved?", Nat Rev Drug Discov, 6, pp.189~201 (2007)
23. Dwyer DS, "Drug discovery based on genetic and metabolic findings in schizophrenia", Expert Rev Clin Pharmacol, 1, pp.773~789 (2008)
24. Leonard BE, "Is there an immunologic basis for schizophrenia?", Expert Rev Clin Immunol, 1, pp.103~112 (2005)
25. Readhead B, "Expression-based drug screening of neural progenitor cells from individuals with schizophrenia", Nat Commun, 9, pp.4412~ (2018)
26. Collier DA, "Advances in the genetics of schizophrenia : toward a network and pathway view for drug discovery", Ann N Y Acad Sci, 1366, pp.61~75 (2016)
27. Reif A, "Neural stem cell proliferation is decreased in schizophrenia, but not in depression", Mol Psychiatry, 11, pp.514~522 (2006)
28. Gorba T, "Neural stem cells as tools for drug discovery : novel platforms and approaches", Expert Opin Drug Discov, 8, pp.1083~1094 (2013)
29. Taupin P, "Therapeutic potential of adult neural stem cells", Recent Pat CNS Drug Discov, 1, pp.299~303 (2006)
30. Rubin LL, "Stem cells and drug discovery : the beginning of a new era?", Cell, 132, pp.549~552 (2008)
31. Smith DA, "The effect of plasma protein binding on in vivo efficacy : misconceptions in drug discovery", Nat Rev Drug Discov, 9, pp.929~939 (2010)
32. Fuentes AV, "Comprehension of top 200prescribed drugs in the US as a resource for pharmacy teaching, training and practice", Pharmacy(Basel), 6, pp.43~ (2018)
33. Gan J, "In vitro screening of 50 highly prescribed drugs for thiol adduct formation--comparison of potential for drug-induced toxicity and extent of adduct formation", Chem Res Toxicol, 22, pp.690~698 (2009)
34. Murdoch D, "Will targeted therapy hold its promise? An evidence-based review", Curr Opin Oncol, 20, pp.104~111 (2008)
35. Eastman P, "OpenMM 7 : rapid development of high performance algorithms for molecular dynamics", PLoS Comput Biol, 13, pp.e1005659~ (2017)
36. Herculano-Houzel S, "The glia", neuron ratio : how it varies uniformly across brain structures and species and what that means for brain physiology and evolution, 2014, pp.62, 1377~1391
37. Turrigiano GG, "Homeostatic plasticity in the developing nervous system", Nat Rev Neurosci, 5, pp.97~107 (2004)
38. Keck T, "Integrating Hebbian and homeostatic plasticity : the current state of the field and future research directions", Philos Trans R Soc Lond B Biol Sci, 372, pp.20160158~ (2017)
39. Berk M, "Three paths to drug discovery in psychiatry", Am J Psychiatry, 172, pp.412~414 (2015)
40. Vatansever S, "Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases : state-of-the-arts and future directions", Med Res Rev, 41, pp.1427~1473 (2021)
41. Zhao K, "Drug repositioning for schizophrenia and depression", anxiety disorders : a machine learning approach leveraging expression data, 2018, pp.23, 1304~1315
42. Marunnan SM, "Development of MLR and SVM aided QSAR models to identify common SAR of GABA uptake herbal inhibitors used in the treatment of schizophrenia", Curr Neuropharmacol, 15, pp.1085~1092 (2017)
43. Sharma G, "Identification of small molecules against the NMDAR : an insight from virtual screening, density functional theory, free energy landscape and molecular dynamics simulation-based findings", Netw Model Anal Health Inform Bioinform, 11, pp.31~ (2022)
44. Udow SJ, "Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease", CMAJ, 190, pp.E50~E52 (2018)
45. Cameron C, "Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications : a retrospective evaluation", J Clin Psychopharmacol, 34, pp.559~564 (2014)
46. Mackie K, "Cannabinoid receptors as therapeutic targets", Annu Rev Pharmacol Toxicol, 46, pp.101~122 (2006)
47. Solmi M, "Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia", CNS Spectr, 22, pp.415~426 (2017)
48. Liu F, "Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia : a double blind, randomized, controlled trial", Schizophr Res, 153, pp.169~176 (2014)
49. Cortez IL, "Are CB2receptors a new target for schizophrenia treatment?", Front Psychiatry, 11, pp.587154~ (2020)
50. Deen M, "Association between sumatriptan treatment during a migraine attack and central 5-HT1B receptor binding", JAMA Neurol, 76, pp.834~840 (2019)
51. Ruf BM, "The 5-HT1B receptor : a novel target for the pathophysiology of depression", Curr Drug Targets, 10, pp.1118~1138 (2009)
52. López-Figueroa AL, "Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia", Biol Psychiatry, 55, pp.225~233 (2004)
53. Mohammadi A, "Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia", Psychiatry Res, 265, pp.25~38 (2018)
54. Sliwoski G, "Discovery of small-molecule modulators of the human Y4 receptor", PLoS One, 11, pp.e0157146~ (2016)
55. DE Hert M, "Metabolic syndrome in people with schizophrenia : a review", World Psychiatry, 8, pp.15~22 (2009)
56. Stuart MJ, "Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment : a systematic review of biomarker studies", Neurosci Biobehav Rev, 42, pp.93~115 (2014)
57. Maeda K, "CCR5 inhibitors : emergence, success, and challenges", Expert Opin Emerg Drugs, 17, pp.135~145 (2012)
58. Kalkonde YV, "The CC chemokine receptor 5 regulates olfactory and social recognition in mice", Neuroscience, 197, pp.153~161 (2011)
59. Dasdemir S, "Chemokine gene variants in schizophrenia", Nord J Psychiatry, 70, pp.407~412 (2016)
60. Rasmussen HB, "Association between the CCR5 32-bp deletion allele and late onset of schizophrenia", Am J Psychiatry, 163, pp.507~511 (2006)
61. Di Nuzzo S, "Exacerbation of paranoid schizophrenia in a psoriatic patient after treatment with cyclosporine A, but not with etanercept", J Drugs Dermatol, 6, pp.1046~1047 (2007)
62. Hauben M, "Cyclosporine neurotoxicity", Pharmacotherapy, 16, pp.576~583 (1996)
63. Sato Y, "Impact of cyclosporine upon emotional and social behavior in mice", Transplantation, 83, pp.1365~1370 (2007)
64. Wijdicks EF, "Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression", Neurology, 45, pp.1962~1964 (1995)
65. St Clair D, "Association within a family of a balanced autosomal translocation with major mental illness", Lancet, 336, pp.13~16 (1990)
66. Kim Y, "Rapamycin increases the incidence of neuropsychiatric illness in kidney transplant patients through the suppression of neural stem cells", Transl Psychiatry, 10, pp.156~ (2020)
67. Şenay O, "Possible involvement of inhibited mTOR signaling in de novo psychosis following the initiation of everolimus in a patient with tuberous sclerosis : a clinical vignette", Psychiatr Clin Psychopharmacol, 29, pp.262~263 (2019)
68. Yui K, "Improvement in impaired social cognition but not seizures by everolimus in a child with tuberous sclerosis-associated autism through increased serum antioxidant proteins and oxidant", antioxidant status, 2019, pp.2019, 2070619~
69. Kim Y, "Hyperactive ACC-MDT pathway suppresses prepulse inhibition in mice", Schizophr Bull, 47, pp.31~43 (2021)
70. Kim Y, "Impaired prepulse inhibition in mice with IRSp53 deletion in modulatory neurotransmitter neurons including dopamine, acetylcholine, oxytocin, and serotonin", Biochem Biophys Res Commun, 586, pp.114~120 (2022)
71. Spark DL, "Beyond antipsychotics : a twenty-first century update for preclinical development of schizophrenia therapeutics", Transl Psychiatry, 12, pp.147~ (2022)
72. Orlovska-Waast S, "Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders : a systematic review and meta-analysis", Mol Psychiatry, 24, pp.869~887 (2019)
73. Upthegrove R, "Neuroinflammation and Schizophrenia", pp.49~66 (2019), Springer

관련 논문AI추천